Study Shows Safety and Efficacy of Imaging Technique for Neuroendocrine Tumors
By MedImaging International staff writers Posted on 25 May 2016 |
Image: The images demonstrate that Ga-68 DOTATATE PET/CT anterior 3D MIP and axial fused images could visualize metastases and change the surgical plan for resection (Photo courtesy of Ronald C. Walker, MD / Journal of Nuclear Medicine).
The results of a new study have demonstrated the safety and efficacy of Ga-68 DOTATATE PET/CT scans, compared to In-111 pentetreotide scans, the current US imaging standard for the detection Neuroendocrine Tumors (NETS).
The study showed that the use of Ga-68 DOTATATE imaging could significantly impact treatment management, resulting in no significant toxicity, a reduction in radiation exposure, and improved accuracy compared to the current standard in the US for the diagnosis and management of NETS. The US FDA has not yet approved the technique.
The study was performed by researchers at the Vanderbilt University Institute of Imaging Science (Nashville, TN, USA) and was published in the May 2016, issue of the Journal of Nuclear Medicine. The researchers enrolled 97 patients with known or suspected pulmonary or gastroenteropancreatic (GEP) NETS.
Corresponding author for the study, Ronald C. Walker, MD, professor of clinical radiology and radiological sciences, Vanderbilt University School of Medicine, said, "Our purpose was to evaluate the safety and efficacy of Ga-68 DOTATATE PET/CT compared to In-111 pentetreotide imaging for diagnosis, staging and re-staging of pulmonary and gastroenteropancreatic neuroendocrine tumors. Hopefully, our investigation will provide sufficient evidence on the safety and efficacy of Ga-68 DOTATATE to the U.S. FDA to allow approval. If so, then patients throughout the United States could soon have access to a higher-quality scan, allowing better patient management decisions while also lowering radiation exposure and shortening examination time."
Related Links:
Vanderbilt University Institute of Imaging Science
The study showed that the use of Ga-68 DOTATATE imaging could significantly impact treatment management, resulting in no significant toxicity, a reduction in radiation exposure, and improved accuracy compared to the current standard in the US for the diagnosis and management of NETS. The US FDA has not yet approved the technique.
The study was performed by researchers at the Vanderbilt University Institute of Imaging Science (Nashville, TN, USA) and was published in the May 2016, issue of the Journal of Nuclear Medicine. The researchers enrolled 97 patients with known or suspected pulmonary or gastroenteropancreatic (GEP) NETS.
Corresponding author for the study, Ronald C. Walker, MD, professor of clinical radiology and radiological sciences, Vanderbilt University School of Medicine, said, "Our purpose was to evaluate the safety and efficacy of Ga-68 DOTATATE PET/CT compared to In-111 pentetreotide imaging for diagnosis, staging and re-staging of pulmonary and gastroenteropancreatic neuroendocrine tumors. Hopefully, our investigation will provide sufficient evidence on the safety and efficacy of Ga-68 DOTATATE to the U.S. FDA to allow approval. If so, then patients throughout the United States could soon have access to a higher-quality scan, allowing better patient management decisions while also lowering radiation exposure and shortening examination time."
Related Links:
Vanderbilt University Institute of Imaging Science
Latest Nuclear Medicine News
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure